Incyte (NASDAQ: INCY) appoints new President and consolidates U.S. commercial

Rhea-AI Filing Summary

Incyte Corporation announced several executive leadership changes. Pablo J. Cagnoni was appointed President, Incyte and Global Head of Research and Development, adding broader enterprise-wide strategic and operational responsibilities while continuing to lead R&D. Steven H. Stein became Executive Vice President, Chief Medical Officer and Head of Late-stage Development, continuing to oversee late-stage programs in Hematology, Oncology and Immunology and Global Medical Affairs.

Mohamed Issa was appointed Executive Vice President and Head of U.S. Commercial, continuing to lead U.S. Oncology and taking on expanded responsibility for U.S. Immunology as these businesses are integrated into a single U.S. commercial organization. William J. Meury remains Chief Executive Officer and a member of the Board, while Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period. The filing states there were no changes to compensation arrangements for the impacted executives in connection with these title changes.

FALSE000087916900008791692026-02-272026-02-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 25, 2026

INCYTE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware			001-12400			94-3136539
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

1801 Augustine Cut-Off Wilmington, DE			19803
(Address of principal executive offices)			(Zip Code)

(302) 498-6700

(Registrant’s telephone number,

including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol			Name of exchange on which registered
Common Stock, $.001 par value per share			INCY			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b—2 of the Securities Exchange Act of 1934 (§ 240.12b—2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 25, 2026, Incyte Corporation (the “Company”) announced title changes for certain current members of its executive leadership team, effective immediately. Pablo J. Cagnoni’s title was changed to President, Incyte and Global Head of Research and Development; Steven H. Stein’s title was changed to Executive Vice President, Chief Medical Officer and Head of Late-stage Development; and Mohamed Issa’s title was changed to Executive Vice President and Head of U.S. Commercial. Dr. Cagnoni replaces William J. Meury as President, Incyte. Mr. Meury remains Chief Executive Officer and a member of the Company’s Board of Directors. Mr. Meury, Dr. Cagnoni, Dr. Stein and Dr. Issa are collectively referred to herein as the “Impacted Executives”.

There were no changes to the compensation arrangements between the Company and any Impacted Executive in connection with these title changes. Further biographical information and a description of the business experience of each of the Impacted Executives is contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on February 10, 2026, which are incorporated herein by reference.

A copy of the Company’s press release announcing the title changes is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibits			Description
99.1			Press release issued by Incyte Corporation dated March 25, 2026.
104			Cover Page Interactive Data File (embedded within the Inline XBLR document).

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 26, 2026
			INCYTE CORPORATION
			By:			/s/ Richard Hoffman
						Richard Hoffman
						Executive Vice President and General Counsel

2

Exhibit 99.1

FOR IMMEDIATE RELEASE

Incyte Announces Executive Leadership Appointments

WILMINGTON, Del. – March 25, 2026 – Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans.

Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni’s scientific leadership, Incyte’s R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRASG12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive.

Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte’s extensive and growing late stage development programs across Hematology, Oncology and Immunology as well as Global Medical Affairs, a critical capability for data generation and reinforcing the Company’s scientific leadership throughout the healthcare community. A highly respected leader at Incyte for more than a decade, Dr. Stein’s scientific judgment, development expertise and patient-centric approach have been instrumental to the Company’s success.

Mohamed Issa, Pharm.D. has been appointed Executive Vice President and Head of U.S. Commercial. In this role, Mr. Issa will continue to oversee the U.S. Oncology business while assuming expanded responsibility for U.S. Immunology. These business units are being integrated into a single U.S. commercial organization to support strategic alignment and execution for new product launches, operational effectiveness and standardization of best practices. Mr. Issa is an experienced executive with a proven track record in new product launch planning and operations across both Oncology and Immunology, and his execution-oriented approach will be critical to sustain commercial performance at Incyte.

“These appointments reflect the significant contributions Pablo, Steven and Mohamed have made to Incyte and the value they continue to bring to the company,” said Bill Meury, Chief Executive Officer, Incyte. “Additionally, we are confident that integrating our U.S. commercial teams into one organization will drive effective launch execution and position Incyte for long-term success.”

As part of the transition, Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period.

For more background on Incyte’s Leadership Team, please visit https://incyte.com/our-company/our-leadership.

About Incyte®

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including any discussion of the strength of Incyte’s enterprise leadership and Incyte’s potential for future growth and long-term success.

These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, as detailed in Incyte’s reports filed with the Securities and Exchange Commission, including its annual report on form 10-K for the year ended December 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements.

#   #   #

Contacts

Media						Investors
media@incyte.com						ir@incyte.com

2

FAQ

What executive leadership changes did Incyte (INCY) announce in this 8-K?

Incyte announced new titles for key executives: Pablo J. Cagnoni became President, Incyte and Global Head of R&D; Steven H. Stein became EVP, Chief Medical Officer and Head of Late-stage Development; and Mohamed Issa became EVP and Head of U.S. Commercial, reflecting expanded leadership roles.

Did Incyte (INCY) change executive compensation with these leadership appointments?

No, the company stated there were no changes to compensation arrangements for the impacted executives in connection with the title changes. Existing compensation agreements for Bill Meury, Pablo Cagnoni, Steven Stein and Mohamed Issa remain in place despite their updated leadership responsibilities.

What is Pablo J. Cagnoni’s new role at Incyte (INCY)?

Pablo J. Cagnoni was appointed President, Incyte and Global Head of Research and Development. He continues overseeing R&D while also supporting enterprise-wide strategic planning and operational execution, reflecting his scientific leadership and role in advancing multiple development programs across Incyte’s pipeline.

How is Incyte (INCY) restructuring its U.S. commercial organization?

Incyte is integrating its U.S. Oncology and U.S. Immunology businesses into a single U.S. commercial organization. Mohamed Issa, now Executive Vice President and Head of U.S. Commercial, will oversee this combined structure to support strategic alignment, new product launches, operational effectiveness and standardized best practices.

Which executive is leaving Incyte (INCY) as part of these changes?

Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period. His departure accompanies the integration of U.S. commercial teams and the expanded responsibilities assigned to Mohamed Issa over the unified U.S. commercial organization.

Does Bill Meury remain CEO of Incyte (INCY) after these appointments?

Yes, Bill Meury remains Chief Executive Officer and a member of Incyte’s Board of Directors. The filing notes that Pablo J. Cagnoni replaces him as President, Incyte, but Meury continues in the CEO role and on the company’s board.

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 10.1 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB